Search Results for: MARKET BRIEF The Market for
MARKET BRIEF – Allergic Rhinitis Immunotherapy: Opportunity Analysis & Forecasts to 2028 March 30, 2020
Rose Joachim, PhD, indicates that while a wide variety of OTC therapies exist for the temporary abatement of AR symptoms, allergen-specific immunotherapy is the only truly disease-modifying therapy available for AR.
MARKET BRIEF – Tumor-Infiltrating Lymphocytes: A New Frontier in Cancer Immunotherapy January 13, 2020
Cheryl L. Barton, PhD, and Bianca Piachaud-Moustakis, PhD, believe the role of TIL therapy as an anticancer therapy in melanoma and possibly other solid tumors holds great promise and could become a viable course of treatment in the future.
MARKET BRIEF – Nothing Degrading About Saving Lives: E3 Ligands Recruiting New Drugs Into the Clinic June 4, 2019
Marianna Tcherpakov, PhD, discusses underexploited strategies, traditional approaches that can be optimized, novel techniques beginning to emerge and pay dividends, and results propelling this field toward better clinical outcomes.
MARKET BRIEF – Alzheimer’s Disease Market Report (2016-2026) October 2, 2018
Akiko Fukui, MSc, indicates that amid several failures, the AD pipeline is large and consists of many novel mechanisms, which makes it an exciting market undergoing rapid changes despite its high risk.
MARKET BRIEF – Preferences for Targeted Therapies & Patient-Centric Approaches Drive Transformations in Oncology Drug Delivery Market May 1, 2017
Frost & Sullivan Analyst Piyush Bansal says although chemotherapy has been successfully used for inhibiting cell growth throughout the past few decades, the side effects of chemotherapy have forced researchers to look for some alternative drugs (and how to effectively deliver them) for all types of cancer.
Cecilia Van Cauwenberghe, MS, Technical Insights Senior Research Analyst, Frost & Sullivan, reports that the proliferation of lower cost microfluidics-based genomics tools offering improved capabilities and allowing more access to end-users is expected to drive this technology for pharmaceutical and biomedical research throughout the next 5 years.
Christi Bird, Senior Industry Analyst, Frost & Sullivan, believes the bleakest outlook provided for the life sciences industry is one without a clear light at the end of the tunnel, and successful companies will buckle down to determine long-term strategies for beating the lackluster numbers expected from a sustained austerity policy.
MARKET BRIEF – Latin America Next-Generation Biosimilars Market: Opportunities & Future Growth March 4, 2014
Lucila Rocca, Healthcare Industry Analyst, Frost & Sullivan, indicates the Latin American Biosimilars market will grow at a significant rate in the next 5 years, and the importance of establishing rigorous regulation will stimulate this market growth.
MARKET BRIEF – The Market for Type 2 Diabetes Therapeutics – Key Findings From a Recent Analysis of Global Drug Development Efforts November 19, 2013
Debbie Toscano, Senior Industry Analyst, Frost & Sullivan, summarizes key findings of Frost & Sullivan’s recent analysis of the type 2 diabetes therapeutics market, which examines in detail the insulin and non-insulin segments of this market on a global level.
MARKET BRIEF – Financial Performance Benchmarking & Competitive Landscape Assessment of Leading CROs November 18, 2013
Adam M. Dion, MS, summarizes GlobalData’s recent CRO Benchmark Report and believes the dynamics of pharmaceutical outsourcing and location decisions in emerging markets are changing. Cost reduction is being augmented and will gradually be eclipsed by footprint growth as a major factor shaping decisions, and CROs are realizing that the ability to be on the ground closer to their customers is a key building block to establishing sustainable, long-term relationships with clients.
MARKET BRIEF – Controlled Release Technologies: Advancing Toward Targeting Therapeutics June 10, 2013
Frost & Sullivan Analyst Cecilia Van Cauwenberghe, MS, reviews a few recent innovative approaches to controlled release technologies with a focus on some of the therapeutic areas most relevant to the current pharmaceuticals market.
MARKET BRIEF – Healthcare Growth Opportunities: Is Brazil the Next Big Thing in Healthcare? December 31, 2012
Frost & Sullivan Analysts Swathi Allada, MBA, and Willian Fujioka believe the Brazilian healthcare market is poised for rapid growth, and the major revenue will come from the pharmaceutical/biotech sector, followed by medical devices, medical imaging, clinical diagnostics, and healthcare IT.
Bill Martineau, MBA, believes LVPs represent one of the highest value-added applications for pharmaceutical packaging. Nonetheless, demand for IV containers will expand at a lackluster pace due to trends promoting short hospital stays and less-invasive surgeries.
MARKET BRIEF – Technology Trends in the Pharmaceutical & Biopharmaceutical Industry February 29, 2012
Frost & Sullivan Analyst Cecilia E. Van Cauwenberghe believes that although the main competitive behavior around the pharmaceutical industry is based on technology differentiation and cost-based strategies, the rules governing the course of the industry are based on a complex understanding of the principal actors’ interaction.
MARKET BRIEF – Stakeholders Portrait in the Pharmaceutical Industry December 31, 2011
Frost & Sullivan Analyst Cecilia E. Van Cauwenberghe says that even though pharmaceutical and biotechnology companies, as with healthcare industry representatives, will continue to play a leading role, many players characterize the current industry landscape with many disciplines and technologies.
2019 Analytical Testing in Drug Development eBook – Regulations Help Propel Testing Market September 6, 2019
This e-Book showcases the various types of services that leading testing companies offer and how they are helping industry comply with regulations to get their products approved and commercialized.
CELL CULTURE MARKET – 3D Cell Cultures: Next Generation & New Challenges November 19, 2015
Kevin James and Robert G. Hunter of BCC Research say significant growth within the biopharmaceuticals industry is spurring unprecedented innovation in and demand for cell culture products for the purposes of drug discovery and safety testing. While 2D cell cultures have been in laboratory use since the 1950s, the market for 3D cultures has witnessed spectacular growth throughout the past decade.
HUMAN FACTORS STUDIES – Human Factors Studies During a Pandemic: How One Company Adapted to Covid-19 Restrictions October 4, 2021
Miranda Newbery says although it is possible to carry out use risk assessments, expert reviews and device comparisons – which do not require contact with end users – these cannot fully replace first-hand user feedback.
Dai Hayward, CEO at Micropore, discusses his company’s expertise and underpinning technology in the development of safe, efficient, and scalable continuous manufacturing of drug delivery solutions.
BIOSIMILAR DEVELOPMENT – Biosimilars: The Process & Quality System Approach to Clinical Applications January 13, 2021
Kaiser Aziz, PhD, addresses biosimilar developments and future innovations with an emphasis placed on quality system approaches to the development and availability of new biosimilar products.